Novavax (NASDAQ:NVAX) director Michael A. McManus has sold 4K shares at an average price of $220.78 per share, according to a regulatory filing released yesterday.
Dated March 19, the transaction valued at $883.1K trims McManus’ total stake at the company by ~30.9% to ~8.9K shares. Novavax is trading ~2.2% higher in the pre-market.
Novavax insiders have sold ~$13M worth company stock in Q1 2021 less than half of the recent peak of $30M recorded in Q3 2020.
Top executives of Novavax have sold ~46M worth company shares in 2020, Reuters reported in January after a review of regulatory filings of the company.
